Allogene Therapeutics, Inc. (ALLO) Tops Q2 EPS by 4c
Tweet
Share
E-mail
Get Alerts ALLO Hot Sheet
Join SI Premium – FREE
Allogene Therapeutics, Inc. (NASDAQ: ALLO) reported Q2 EPS of ($0.23), $0.04 better than the analyst estimate of ($0.27).
For earnings history and earnings-related data on Allogene Therapeutics, Inc. (ALLO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UBS Downgrades Core Natural Resources (CNR) to Neutral
- Keysight Technologies (KEYS) Tops Q3 EPS by 59c; Offers Guidance
- Morgan Stanley Upgrades Honeywell Aerospace Inc (HONA) to Overweight
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
